Literature DB >> 28508305

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.

Katsutoshi Oda1, Michihiro Tanikawa2, Kenbun Sone2, Mayuyo Mori-Uchino2, Yutaka Osuga2, Tomoyuki Fujii2.   

Abstract

Poly (ADP-ribose) polymerase (PARP) inhibitors have attracted much attention as one of the major molecular-targeted therapeutics for inhibiting DNA damage response. The PARP inhibitor, olaparib, has been clinically applied for treating certain recurrent ovarian cancer patients with BRCA1/2 mutations in Europe and the United States. It was also designated on 24 March 2017 as an orphan drug in Japan for similar clinical indications. In this review, we discuss (i) the prevalence of BRCA1/2 mutations in ovarian cancer, (ii) clinical trials of PARP inhibitors in ovarian cancer, (iii) genetic counseling for hereditary breast and ovarian cancer patients, and (iv) non-BRCA genes that may be associated with homologous recombination deficiency.

Entities:  

Keywords:  BRCA1; BRCA2; Hereditary breast and ovarian cancer; Homologous recombination deficiency; PARP inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28508305     DOI： 10.1007/s10147-017-1137-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


  66 in total

Review 1.  Homologous repair of DNA damage and tumorigenesis: the BRCA connection.

Authors:  Maria Jasin
Journal:  Oncogene       Date:  2002-12-16       Impact factor: 9.867

2.  A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Katherine Bell-McGuinn; Carol Aghajanian; Heidi J Gray; Krishnansu S Tewari; Steven C Rubin; Thomas J Rutherford; John K Chan; Alice Chen; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2015-03-24       Impact factor: 5.482

3.  Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.

Authors:  Barbara M Norquist; Kathryn P Pennington; Kathy J Agnew; Maria I Harrell; Christopher C Pennil; Ming K Lee; Silvia Casadei; Anne M Thornton; Rochelle L Garcia; Tom Walsh; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2012-12-19       Impact factor: 5.482

4.  Inherited Mutations in Women With Ovarian Carcinoma.

Authors:  Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer
Journal:  JAMA Oncol       Date:  2016-04       Impact factor: 31.777

5.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

6.  Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.

Authors:  Arti Yadav; Bhavna Kumar; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2011-05-06       Impact factor: 6.261

7.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

8.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

9.  BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.

Authors:  Marie Soegaard; Susanne Kruger Kjaer; Mark Cox; Eva Wozniak; Estrid Høgdall; Claus Høgdall; Jan Blaakaer; Ian J Jacobs; Simon A Gayther; Susan J Ramus
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

10.  Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas.

Authors:  Yuriko Uehara; Katsutoshi Oda; Yuji Ikeda; Takahiro Koso; Shingo Tsuji; Shogo Yamamoto; Kayo Asada; Kenbun Sone; Reiko Kurikawa; Chinami Makii; Otoe Hagiwara; Michihiro Tanikawa; Daichi Maeda; Kosei Hasegawa; Shunsuke Nakagawa; Osamu Wada-Hiraike; Kei Kawana; Masashi Fukayama; Keiichi Fujiwara; Tetsu Yano; Yutaka Osuga; Tomoyuki Fujii; Hiroyuki Aburatani
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240
View more
  4 in total

Review 1.  Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.

Authors:  Domenica Lorusso; Elisa Tripodi; Giuseppa Maltese; Stefano Lepori; Ilaria Sabatucci; Giorgio Bogani; Francesco Raspagliesi
Journal:  Drug Des Devel Ther       Date:  2018-05-29       Impact factor: 4.162

2.  PARI functions as a new transcriptional target of FOXM1 involved in gastric cancer development.

Authors:  Yi Zhang; Xiaojuan Ye; Lizhi Chen; Qiong Wu; Yong Gao; Yandong Li
Journal:  Int J Biol Sci       Date:  2018-04-05       Impact factor: 6.580

3.  Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.

Authors:  Isaac E Kim; Sinae Kim; Arnav Srivastava; Biren Saraiya; Tina Mayer; Wun-Jae Kim; Isaac Yi Kim
Journal:  BMC Urol       Date:  2019-05-06       Impact factor: 2.264

4.  TGF-β signaling proteins and CYP24A1 may serve as surrogate markers for progesterone calcitriol treatment in ovarian and endometrial cancers of different histological types.

Authors:  Ana Paucarmayta; Hannah Taitz; Yovanni Casablanca; Gustavo C Rodriguez; G Larry Maxwell; Kathleen M Darcy; Viqar Syed
Journal:  Transl Cancer Res       Date:  2019-08       Impact factor: 1.241
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.